Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: OAT 889; OATD 01

Latest Information Update: 24 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yale University
  • Developer OncoArendi Therapeutics
  • Class Antiasthmatics; Antifibrotics; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Acidic mammalian chitinase inhibitors; Chitinase inhibitors; Chitotriosidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Asthma; Interstitial lung diseases
  • Preclinical Chronic obstructive pulmonary disease

Most Recent Events

  • 17 May 2019 Adverse events data from a phase I trial in Asthma (In volunteers) presented at the 115th International Conference of the American Thoracic Society (ATS-2019)
  • 29 Oct 2018 OncoArendi Therapeutics has patent protection for OATD 01 in USA (OncoArendi Therapeutics pipeline, October 2018)
  • 29 Oct 2018 OncoArendi Therapeutics completes a phase I trial in Asthma (In volunteers) in Germany, before October 2018 (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top